In this issue:
HIV, HPV & HNSCC risk in veterans
Nivolumab following salvage resection in recurrent HNSCC
Gene mutations & clinicopathologic features in EACSCC
NK cells with cetuximab for recurrent/metastatic NPC
Anti-PD-1 therapy in OSCC
A nomogram for suitability of induction chemo & concurrent chemoradiotherapy for N-stage NPC
Immunological changes with GP chemo in NPC
Two vs. three cycles of neoadjuvant chemo in children & adolescents with NPC
Anti-PD-1 ± ipilimumab for mucosal melanoma
Lenvatinib for anaplastic thyroid cancer
Please login below to download this issue (PDF)